Novartis’ Hepatitis C Drug Alisporivir Returns To Clinical Testing Minus Interferon
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II trial of alisporivir plus ribavirin began after FDA modified its partial clinical hold; previous regimen included peg-interferon.